This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Coninck, E. C. Articles by Hoppe, R. T. Search for Related Content PubMed PubMed Citation Articles by de Coninck, E. C. Articles by Hoppe, R. T. Social Bookmarking                            What's this?

Clinical Characteristics and Outcome of Patients With Extracutaneous Mycosis Fungoides

From the Departments of Dermatology and Radiation Oncology, Stanford University School of Medicine, Stanford, CA.

Address reprint requests to Youn H. Kim, MD, Associate Professor, Department of Dermatology, Stanford University Medical Center, 900 Blake Wilbur Dr, #W0069, Palo Alto, CA 94304; email: younkim{at}stanford.edu

PURPOSE: To identify prognostic factors predictive of outcome in patients with extracutaneous (stage IV) mycosis fungoides (MF) and to evaluate the risk of progression to extracutaneous disease by initial extent of skin involvement.

PATIENTS AND METHODS: One hundred twelve patients with extracutaneous disease at presentation or with progression and 434 patients with initial cutaneous-only disease were identified. Actuarial survival curves were plotted according to the Kaplan-Meier technique.

RESULTS: The median survival of all stage IV patients was 13 months from the date of first treatment for stage IV disease. Sex, race, age, extent of skin involvement, and peripheral blood Sezary cell involvement were not significant to survival outcome. Eleven patients (10%) had a complete response to therapy resulting in a significantly improved median survival compared with patients with a partial or no response (1.70 v 0.91 years, P = .047 and 1.70 v 0.57 years, P = .011, respectively). At 20 years from diagnosis, the risk for progression to extracutaneous disease by initial extent of skin involvement was 0% for limited patch/plaque, 10% for generalized patch/plaque, 35.5% for tumorous disease, and 41% for erythrodermic involvement.

CONCLUSION: This was a larger scale study over a longer time period than had been completed previously on extracutaneous MF. Prognostic factors important in the cutaneous stages of disease are no longer significant once extracutaneous disease develops. Patients who had a more favorable response to therapy may have had a biologically less aggressive disease than their less fortunate counterparts. The risk of developing stage IV MF is highest in patients presenting with tumorous or erythrodermic skin disease and is lowest in patients with limited skin involvement.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. O. Arulogun, H. M. Prince, J. Ng, S. Lade, G. F. Ryan, O. Blewitt, and C. McCormack Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation Blood, October 15, 2008; 112(8): 3082 - 3087. [Abstract] [Full Text] [PDF]

				H. Yano, T. Ishida, A. Inagaki, T. Ishii, J. Ding, S. Kusumoto, H. Komatsu, S. Iida, H. Inagaki, and R. Ueda Defucosylated Anti CC Chemokine Receptor 4 Monoclonal Antibody Combined with Immunomodulatory Cytokines: A Novel Immunotherapy for Aggressive/Refractory Mycosis Fungoides and Sezary Syndrome Clin. Cancer Res., November 1, 2007; 13(21): 6494 - 6500. [Abstract] [Full Text] [PDF]

				E. Olsen, E. Vonderheid, N. Pimpinelli, R. Willemze, Y. Kim, R. Knobler, H. Zackheim, M. Duvic, T. Estrach, S. Lamberg, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) Blood, September 15, 2007; 110(6): 1713 - 1722. [Abstract] [Full Text] [PDF]

				E. A. Olsen, Y. H. Kim, T. M. Kuzel, T. R. Pacheco, F. M. Foss, S. Parker, S. R. Frankel, C. Chen, J. L. Ricker, J. M. Arduino, et al. Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma J. Clin. Oncol., July 20, 2007; 25(21): 3109 - 3115. [Abstract] [Full Text] [PDF]

				E. Y. Tsai, A. Taur, L. Espinosa, A. Quon, D. Johnson, S. Dick, S. Chow, R. Advani, R. Warnke, S. Kohler, et al. Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol, May 1, 2006; 142(5): 577 - 584. [Abstract] [Full Text] [PDF]

				C. Assaf, M. Hummel, M. Steinhoff, C. C. Geilen, H. Orawa, H. Stein, and C. E. Orfanos Early TCR-{beta} and TCR-{gamma} PCR detection of T-cell clonality indicates minimal tumor disease in lymph nodes of cutaneous T-cell lymphoma: diagnostic and prognostic implications Blood, January 15, 2005; 105(2): 503 - 510. [Abstract] [Full Text] [PDF]

				Y. H. Kim, H. L. Liu, S. Mraz-Gernhard, A. Varghese, and R. T. Hoppe Long-term Outcome of 525 Patients With Mycosis Fungoides and Sezary Syndrome: Clinical Prognostic Factors and Risk for Disease Progression Arch Dermatol, July 1, 2003; 139(7): 857 - 866. [Abstract] [Full Text] [PDF]

				Y. H. Kim, G. Martinez, A. Varghese, and R. T. Hoppe Topical Nitrogen Mustard in the Management of Mycosis Fungoides: Update of the Stanford Experience Arch Dermatol, February 1, 2003; 139(2): 165 - 173. [Abstract] [Full Text] [PDF]

				J. P. Greer, M. C. Kinney, and T. P. Loughran Jr. T Cell and NK Cell Lymphoproliferative Disorders Hematology, January 1, 2001; 2001(1): 259 - 281. [Abstract] [Full Text] [PDF]